Prognostic Implications of Timing of Immunotherapy in Stage IV Non-Small Cell Lung Cancer.

ABSTRACT:

Background

Currently, the established approach for addressing stage IV non-small cell lung cancer (NSCLC) involves combining chemotherapy with immunotherapy. However, the necessity for molecular analysis prior to commencing immunotherapy often results in a delay in its initiation following the commencement of chemotherapy. Therefore, this study aimed to study the significance of postponing immunotherapy on pertinent patient outcomes.

Methods

Using the National Cancer Database (NCBD), patients diagnosed with stage IV NSCLC between 2017 and 2018 were screened. Inclusion criteria comprised those treated with multi-agent chemotherapy as the first-line therapy within 30 days of treatment, surviving beyond 2 months of diagnosis, and absence of neuroendocrine pathology. Patients we

SUBMITTER: Vazquez-Urrutia JR 

PROVIDER: S-EPMC11424121 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature